The region of chromosome 9 known as 9p21 harbors one of the most consistently replicated type 2 diabetes risk signals in the human genome. rs564398 sits within CDKN2B-AS1 (ANRIL)¹¹ CDKN2B-AS1 (ANRIL)
ANRIL stands for "antisense non-coding RNA in the INK4 locus" — a long non-coding RNA transcribed in the opposite direction from the CDKN2A and CDKN2B protein-coding genes at 9p21. lncRNAs regulate nearby gene expression through chromatin remodeling and other epigenetic mechanisms. — a long non-coding RNA that modulates expression of the adjacent tumor suppressor genes CDKN2A (p16) and CDKN2B (p15). These inhibitors act as brakes on cell division, and in pancreatic beta cells they control how readily the insulin-producing mass can renew itself.

rs564398 is a secondary signal at this locus, independent of but weaker than the primary variant rs10811661 (~200 kb away). The T risk allele carries a per-allele T2D odds ratio of approximately 1.08, compared to ~1.24 for the primary signal. Both act through the same broad mechanism — reducing glucose-stimulated beta-cell proliferative capacity — but may tag distinct regulatory elements within the locus.

The Mechanism

The 9p21 locus regulates how effectively pancreatic beta cells can replicate in response to metabolic demand. Unlike T2D variants that impair acute insulin secretion per cell (e.g., TCF7L2 or SLC30A8), rs564398 acts at the level of beta-cell mass maintenance²² beta-cell mass maintenance
Beta cells must periodically replace themselves as they age or are damaged by metabolic stress. The total number of functional beta cells declines over decades if renewal capacity is impaired, eventually reducing the pancreas's ability to secrete enough insulin..

A functional study by Kong et al. 2018³³ Kong et al. 2018
Kong Y et al. CDKN2A/B T2D Genome-Wide Association Study Risk SNPs Impact Locus Gene Expression and Proliferation in Human Islets. Diabetes 2018. PMID:29432124 measured BrdU incorporation (a direct index of cell division) in 43 human islet preparations cultured at high versus normal glucose concentrations. Islets carrying one or two T risk alleles at rs564398 showed significantly lower glucose-stimulated proliferation than CC homozygous islets — directly linking the variant to impaired beta-cell renewal under metabolic challenge. Notably, rs564398 did not alter expression of p14, p15, p16, or MTAP in islets, suggesting its mechanism operates through ANRIL at a regulatory level distinct from simple CDKN2A/B transcript abundance.

The Evidence

The T risk allele at rs564398 was first reported as a T2D susceptibility signal in the landmark WTCCC GWAS⁴⁴ WTCCC GWAS
Zeggini et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007. PMID:17463249, where it reached genome-wide significance with OR 1.13 (95% CI 1.08–1.19, p = 1×10⁻⁶). This was one of the largest initial T2D GWAS, covering ~1,900 cases from the WTCCC plus replication in ~3,700 additional cases.

The Cugino et al. 2012 meta-analysis⁵⁵ Cugino et al. 2012 meta-analysis
Cugino et al. Type 2 diabetes and polymorphisms on chromosome 9p21: a meta-analysis. Nutr Metab Cardiovasc Dis 2012. PMID:21315566 of 22 chromosome 9p21 studies quantified the rs564398 signal at OR 1.08 (95% CI 1.05–1.12) with a population attributable risk of 6% — roughly half the PAR of the primary rs10811661 signal (15%). A further meta-analysis⁶⁶ further meta-analysis
Peng et al. The relationship between five widely-evaluated variants in CDKN2A/B and CDKAL1 genes and the risk of type 2 diabetes: a meta-analysis. Gene 2013. PMID:24012816 of 16 studies (20,029 cases, 24,419 controls) found a significant association in Caucasians (OR 1.19, p=0.012) but not in Asians (OR 1.01, p=0.868), with marked ethnic heterogeneity at this SNP.

The C allele frequency varies substantially across populations — ~41% in Europeans, ~34% globally, ~13% in East Asians, and ~7% in Africans. This population stratification mirrors the primary 9p21 signal and may partially explain the stronger T2D associations observed in European cohorts.

Practical Actions

Because the 9p21 locus reduces beta-cell renewal capacity rather than impairing acute insulin secretion, the relevant intervention strategy centers on reducing cumulative metabolic demand on a beta-cell pool that has limited ability to self-replenish. This means:

• Keeping postprandial glucose excursions small by choosing low-glycemic-load carbohydrates (legumes, lentils, non-starchy vegetables) reduces the secretory burden on each individual beta cell.
• Periodic fasting glucose and HbA1c monitoring allows detection of gradually declining beta-cell reserve before frank diabetes develops.
• Minimizing direct beta-cell stressors (excess fructose, saturated fat overload) is specifically relevant when renewal capacity is genetically constrained.

Interactions

rs564398 and the primary 9p21 SNP rs10811661 are approximately 104 kb apart and are not in complete linkage disequilibrium — they may represent independent regulatory signals within the locus. Carrying risk alleles at both SNPs could compound the impairment of beta-cell renewal through distinct regulatory elements within ANRIL and flanking chromatin.

Beyond the 9p21 locus, the 9p21 beta-cell mass signal acts through a mechanism completely distinct from the TCF7L2 pathway (rs7903146), which impairs incretin-stimulated insulin secretion per cell. Individuals carrying risk alleles at both loci face additive T2D susceptibility from two independent mechanisms: reduced beta-cell mass (9p21) and reduced per-cell insulin output (TCF7L2).

The ANRIL locus also carries well-established cardiovascular disease associations; rs564398 has been linked to coronary artery disease risk in a Turkish cohort, particularly in females, highlighting the pleiotropic role of this genomic region.

The follicle-stimulating hormone receptor (FSHR) sits on the surface of granulosa cells in the ovary and Sertoli cells in the testes, where it receives FSH signals that drive follicle development, oocyte maturation, and sperm production. The N680S variant — a single amino acid change at position 680 from asparagine (N) to serine (S) — sits in the intracellular portion of the receptor and alters how quickly and strongly the receptor responds to FSH¹¹ alters how quickly and strongly the receptor responds to FSH
The variant is in the intracellular signaling domain, not the FSH-binding domain. This difference in receptor kinetics has direct, measurable consequences for ovarian stimulation outcomes and is increasingly being used to personalize IVF treatment protocols.

The Mechanism

When FSH binds to its receptor, the intracellular domain triggers a cascade: it activates a Gs protein, which stimulates adenylyl cyclase to produce cyclic AMP (cAMP), which in turn activates protein kinase A and downstream gene expression. The N680S variant changes the kinetics of this cAMP cascade²² The N680S variant changes the kinetics of this cAMP cascade
Not the peak response, but the time to reach it. Granulosa cells from NN homozygotes reach their cAMP plateau in approximately 45 minutes, while SS homozygote cells take approximately 90 minutes. This slower kinetic response in S-carriers results in lower immediate sensitivity to FSH at any given dose³³ lower immediate sensitivity to FSH at any given dose
The receptor reaches full activation later, requiring higher circulating FSH to achieve the same effect over a treatment window. The effect propagates downstream: phospho-ERK1/2 activation, AREG and STARD1 gene expression, and progesterone production are all qualitatively and quantitatively different between NN and SS cells exposed to the same FSH concentration.

The Evidence

The clinical consequence of this receptor kinetic difference is striking. A 2019 study of 586 women undergoing controlled ovarian stimulation⁴⁴ A 2019 study of 586 women undergoing controlled ovarian stimulation
Alviggi et al. Pharmacogenetics and Genomics found that NN carriers (Asn/Asn) produced significantly more oocytes (16±8) compared to carriers of at least one S allele (11±6) despite receiving 20% lower FSH doses. Critically, none of the women who developed ovarian hyperstimulation syndrome (OHSS) — a potentially dangerous overresponse to FSH — had the CC genotype, while the odds ratio for OHSS in NN carriers was 1.7 (P=0.04). This makes biological sense: the faster, stronger receptor response in NN carriers means the same FSH dose produces a larger follicular cohort response.

A 2014 meta-analysis of 13 studies involving 4,020 women⁵⁵ A 2014 meta-analysis of 13 studies involving 4,020 women
Yao et al. Journal of Ovarian Research confirmed that the GG (SS) genotype carries an odds ratio of 1.61 for poor ovarian response (though with borderline significance, P=0.08), while N-allele carriers showed a statistically significant increased risk of hyperresponse (OR 1.47, 95% CI 1.05–2.04, P=0.02). This asymmetric risk profile — GG more likely to underrespond, AA more likely to overrespond — has direct implications for starting dose selection.

A key 2025 trial took the logical next step: 475 women were genotyped before IVF and assigned to genotype-matched gonadotropin types⁶⁶ 475 women were genotyped before IVF and assigned to genotype-matched gonadotropin types
Recombinant FSH for NN carriers, urinary FSH for S-allele carriers. The optimally treated group achieved a live birth rate of 40% versus 29% in non-genotyped controls (OR 1.55, 95% CI 1.23–1.96, P<0.001). This establishes that the biological difference translates into meaningful clinical improvements when treatment is personalized.

The variant also matters for men. A pharmacogenetic study of 89 idiopathic infertile men⁷⁷ A pharmacogenetic study of 89 idiopathic infertile men
Simoni et al. Human Reproduction 2016 found that FSH treatment (using recombinant FSH) improved sperm DNA fragmentation index significantly only in NN homozygous men, not in SS carriers. The mechanism mirrors the female data: NN men have a more FSH-responsive receptor in Sertoli cells.

Population frequencies differ notably by ancestry. In European populations, approximately 30% are NN, 50% NS, and 20% SS. In East Asian women, the AA (NN) genotype is more common at approximately 47%, which may partially explain some population differences in ovarian stimulation response rates reported in clinical studies.

Practical Implications

The clinical applications of FSHR genotyping are clearest in an IVF context. Women who know their FSHR N680S genotype before stimulation can work with their reproductive endocrinologist to:

• CC carriers (SS): Start with higher FSH doses to overcome reduced receptor sensitivity. Urinary FSH (uFSH, which contains additional gonadotropin components) shows better outcomes than recombinant FSH (rFSH) in S-allele carriers in clinical trials.
• TT carriers (NN): Use lower starting doses and monitor closely for OHSS. Recombinant FSH (rFSH) shows better outcomes in NN carriers. A "freeze-all" embryo strategy or GnRH agonist trigger should be considered prophylactically.
• TC carriers (NS): Intermediate response; standard protocols apply but monitoring remains important.

Outside of ART, the variant affects basal reproductive hormone levels. Women with GG (SS) have measurably higher day-3 FSH levels⁸⁸ Women with GG (SS) have measurably higher day-3 FSH levels
9.2 vs 6.2 mIU/ml for TT carriers, P=0.011 — the body compensates for reduced receptor sensitivity by secreting more FSH. This can make CC carriers appear to have "diminished ovarian reserve" on a simple FSH test even when their actual reserve is normal. An anti-Müllerian hormone (AMH) test, which is not affected by FSH receptor sensitivity, provides a more genotype-independent measure of ovarian reserve.

Interactions

rs6165 (FSHR Thr307Ala): This variant in the same gene is in very high linkage disequilibrium with N680S⁹⁹ very high linkage disequilibrium with N680S
D'=0.997, r²=0.82–0.99 across populations. They are almost always inherited together and form a haplotype (GG = Ala307/Ser680, AA = Thr307/Asn680). Most studies of "FSHR polymorphisms" have examined both variants together; their effects are nearly inseparable in clinical research.

LHCGR rs2293275 (N312S): The LH receptor N312S variant interacts with FSHR N680S in determining IVF outcomes. Women who are SS at both FSHR N680S and LHCGR N312S positions ("4S") had a 62% live birth rate across three IVF cycles versus 43–47% for other combined genotypes¹⁰¹⁰ Women who are SS at both FSHR N680S and LHCGR N312S positions ("4S") had a 62% live birth rate across three IVF cycles versus 43–47% for other combined genotypes
Adjusted HR 1.89, P=0.049. This interaction between FSH and LH receptor sensitivity defines a pharmacogenetic profile that appears to respond particularly well to ART, potentially because enhanced sensitivity to both FSH and LH creates an optimally responsive gonadal axis.

Compound implication for FSHR GG + LHCGR SS: Women who carry GG at rs6166 and also carry the serine-serine genotype at rs2293275 (LHCGR N312S) may have a combined receptor sensitivity profile that unexpectedly improves IVF outcomes despite individual poor-response signals. These women may represent a distinct pharmacogenetic subgroup that deserves specific protocol design.

Most genetic variants in the FADS gene cluster reduce enzyme activity. rs968567 works differently: the minor T allele turns up delta-6 desaturase (D6D¹¹ D6D
FADS2 — the enzyme that adds a double bond at the sixth carbon position, the rate-limiting first step in converting dietary linoleic acid to GLA and alpha-linolenic acid to stearidonic acid). Instead of blocking PUFA synthesis, T allele carriers push the omega-6 and omega-3 pathways faster — generating more downstream products from dietary precursors. The consequences are nuanced: accelerated conversion boosts EPA production from plant ALA, but also drives more arachidonic acid from omega-6 sources, with opposing effects on inflammatory signalling depending on dietary context.

The Mechanism

rs968567 sits in the promoter region of FADS2 on chromosome 11 (position 61,828,092, GRCh38). The critical molecular finding²² critical molecular finding
Lattka et al. A common FADS2 promoter polymorphism increases promoter activity and facilitates binding of transcription factor ELK1. J Lipid Res, 2010 is that the T allele creates a binding site for ELK1, a member of the ETS transcription factor family. When ELK1 binds, it drives higher FADS2 mRNA transcription. The C allele does not create this binding site, leaving D6D expression at its baseline. Luciferase reporter assays across three cell lines confirmed allele-dependent differences in promoter activity, establishing rs968567 as a functional, mechanistically-explained regulatory variant — not simply a tag for a nearby causal site.

D6D catalyses two parallel reactions: (1) linoleic acid (LA, the dominant dietary omega-6) → gamma-linolenic acid (GLA) → DGLA → arachidonic acid (AA); (2) alpha-linolenic acid (ALA, the plant omega-3) → stearidonic acid (SDA) → eicosatetraenoic acid (ETA) → EPA. Higher D6D activity in T allele carriers means both pathways run faster from the same precursor intake, but whether that produces a net benefit or a net risk depends critically on the ratio of omega-6 to omega-3 in the diet.

The Evidence

The functional promoter finding was validated physiologically in the HELENA study³³ HELENA study
Bokor et al. Single nucleotide polymorphisms in the FADS gene cluster are associated with delta-5 and delta-6 desaturase activities estimated by serum fatty acid ratios. J Lipid Res, 2010 — 1,144 European adolescents across seven countries. Of all FADS2 SNPs tested, rs968567 was the only one specifically and significantly associated with higher estimated D6D activity (p=1.5×10⁻⁶). This directly connects the ELK1-driven promoter upregulation seen in cell assays to measurable enzyme activity variation in living humans.

The effect extends to the earliest stage of human development. In the ALSPAC birth cohort⁴⁴ ALSPAC birth cohort
Lattka et al. Umbilical cord PUFA are determined by maternal and child fatty acid desaturase (FADS) genetic variants in the Avon Longitudinal Study of Parents and Children (ALSPAC). Br J Nutr, 2013, analysing >2,000 mother-child pairs, rs968567 was one of only two FADS2 variants with specific, independent effects on umbilical cord plasma PUFA composition. This means D6D activity differences from rs968567 are not a post-natal diet interaction — they shape fetal fatty acid availability during development.

The net effect on circulating fatty acids in healthy young adults⁵⁵ healthy young adults
Roke et al. Variation in the FADS1/2 gene cluster alters plasma n-6 PUFA. Prostaglandins Leukot Essent Fatty Acids, 2013 follows predictably: FADS gene cluster minor allele carriers (including rs968567 T allele carriers) showed lower circulating AA and reduced desaturase indices. This appears paradoxical given the T allele elevates D6D — but the explanation lies in genetic LD: rs968567 T allele tags a haplotype that, across the cluster, tracks with different product ratios than the isolated promoter effect would predict. The promoter activity study and the desaturase index study together frame the actual phenotype: elevated D6D at rs968567 specifically shifts flux through both pathways, but the net plasma AA outcome depends on the full FADS haplotype background.

Practical Actions

The key dietary implication of elevated D6D activity is that the balance between omega-6 and omega-3 precursor intake matters more than for people with baseline D6D. T allele carriers convert LA to AA more efficiently: on a Western diet high in linoleic acid (from vegetable oils, processed foods), this produces more arachidonic acid and its pro-inflammatory eicosanoids. The same elevated D6D also converts ALA to SDA and further to EPA more efficiently — meaning T allele carriers are better responders to plant-based omega-3 sources, and better responders to EPA/DHA supplementation when baseline intake is adequate.

The practical priority is managing the omega-6 load specifically — reducing high-LA vegetable oils (soybean, sunflower, corn oil) and replacing with low-LA alternatives (olive oil, macadamia oil, avocado oil) directly limits the AA overproduction that elevated D6D can drive.

Interactions

rs968567 sits on chromosome 11q12.2 in proximity to the broader FADS1/FADS2/FADS3 gene cluster. The promoter variant acts upstream of the FADS2 coding sequence; coding or intronic variants in the same gene (rs174568, rs174575, rs174553) that reduce D6D expression can partially offset the T allele's upregulation effect when co-inherited on the opposite haplotype. For users with both rs968567 T allele and a FADS1 reduced-activity variant (such as rs174541 or rs174547), the downstream pathway is complex: FADS2 elevates EPA substrate supply via faster ALA conversion, but the impaired FADS1 delta-5 step still limits the final EPA yield. The net omega-3 status in this combination depends on both steps — supplementing with preformed EPA/DHA remains the most reliable strategy regardless of which FADS enzyme is rate-limiting.

Two adjacent promoter variants in the ADH5 gene sit within a potential NF-κB binding site¹¹ NF-κB binding site
NF-κB (nuclear factor kappa B) is a transcription factor that drives inflammatory gene expression; it binds to specific DNA sequences (kappa B elements) in gene promoters to switch on transcription. rs2851301 is one of these two sites. The hypothesis is that the minor T allele disrupts this binding site — preventing NF-κB from switching on GSNOR transcription during inflammatory episodes — and that this leads to higher levels of the airway bronchodilator S-nitrosoglutathione (GSNO), reducing the risk of asthma.

The Mechanism

ADH5 encodes GSNOR (S-nitrosoglutathione reductase), the enzyme responsible for degrading GSNO in airway lining fluid. GSNO is the primary endogenous bronchodilator in the lungs: it relaxes bronchial smooth muscle at nanomolar concentrations, roughly 100 times more potently than theophylline. In asthmatic airways, total S-nitrosothiol levels are approximately halved²² total S-nitrosothiol levels are approximately halved
Que et al. 2009 measured SNO levels of 11.2 pmol/ml in mild asthmatics vs 23.1 pmol/ml in healthy controls (p=0.01); GSNOR activity was correspondingly elevated at 1,223 vs 537 AU/mg protein (p=0.03).

The NF-κB inflammatory pathway normally upregulates GSNOR during airway inflammation — a paradoxical response that removes the very bronchodilator needed to resolve smooth muscle spasm. rs2851301 and the adjacent rs2602899 lie within a predicted NF-κB response element in the ADH5 promoter. The proposed model: the minor T allele at rs2851301 (or the corresponding allele at rs2602899) disrupts the NF-κB consensus sequence, blunting the inflammation-driven spike in GSNOR transcription. This keeps GSNO levels higher during inflammatory challenge, maintaining bronchodilator reserve precisely when it is most needed.

GSNOR also detoxifies formaldehyde via the glutathione adduct S-hydroxymethylglutathione. Environmental formaldehyde load (from pressed-wood furniture, carpets, cigarette smoke) competes for GSNOR enzyme capacity; T-allele carriers who have lower baseline GSNOR expression may have modestly less formaldehyde clearance capacity, though this has not been directly studied.

The Evidence

rs2851301 was not directly genotyped in the primary association study. Wu et al. 2007³³ Wu et al. 2007
532 nuclear families with asthmatic children aged 4–17 years in Mexico City; family-based association testing using case-parent triads genotyped seven tagging SNPs across the ADH5 locus. The significant protective signal came from rs1154404 (intron 1), where each copy of the minor allele reduced childhood asthma risk (RR 0.77 for one copy, 95% CI 0.61–0.97, P = 0.028; RR 0.66 for two copies, 95% CI 0.44–0.99, P = 0.046). The authors noted that rs1154404 is in near-complete LD (r² = 0.99) with two adjacent promoter SNPs — rs2602899 and rs2851301 — at the NF-κB site, proposing these as the functional variants responsible for the protective signal.

rs2851301 is therefore an inferred protective variant: it tracks the rs1154404 signal almost perfectly, and the biological logic of an NF-κB site disruption at the GSNOR promoter is well-supported by the functional data showing that GSNOR activity correlates with airway hyperresponsiveness. However, because the two promoter variants sit adjacent to each other (complicating direct genotyping) and were not independently associated in a study powered for that purpose, the evidence level for rs2851301 specifically remains emerging.

A 2017 review Barnett & Buxton⁴⁴ Barnett & Buxton
Critical Reviews in Biochemistry and Molecular Biology, vol 52: 340–354; comprehensively reviews GSNOR biology and disease associations reinforces the therapeutic rationale by noting that GSNOR inhibitors (N6022, N91115) have entered clinical trials for asthma and cystic fibrosis, confirming that the enzyme is a validated drug target whose activity level is causally relevant to airway disease.

Practical Actions

For CC carriers (common genotype, ~37% of people), the NF-κB site is intact and GSNOR may respond normally to inflammatory upregulation. Minimising triggers that further stress the GSNOR-GSNO axis — particularly indoor formaldehyde from pressed-wood furniture — is a genotype-specific precaution for those with asthma or atopic history.

For TT carriers (~15% globally), the proposed disruption of the NF-κB site may blunt inflammatory GSNOR upregulation, helping maintain GSNO levels during asthma exacerbations. This protective effect is most relevant in childhood and may attenuate with age. Nitrate-rich vegetables support the inorganic nitrate–nitrite–NO pathway as an independent source of airway bronchodilation.

Interactions

rs2851301 and rs2602899 are two adjacent SNPs at the same NF-κB element; they travel together (r² ≈ 1) and their combined allele state defines the protective haplotype. rs1154404 (intron 1) tags this haplotype with near-perfect precision and is the most studied marker for the protective signal. The high-risk end of the ADH5 allele spectrum is anchored by rs28730619, which tags a haplotype associated with elevated GSNOR activity and 60% increased childhood asthma risk — the mirror image of the rs2851301 protective signal.

The ADRB2 Arg16Gly variant (rs1042713) interacts with GSNOR haplotypes in predicting bronchodilator response to albuterol in Hispanic asthmatic children. For individuals carrying risk variants at both loci, standard short-acting beta-agonist therapy may be less effective.

The MAPT gene encodes tau, a microtubule-stabilising protein central to several neurodegenerative diseases. The gene sits within a large chromosomal inversion on 17q21 that divides all humans into two broad haplotype clades: H1 (no inversion) and H2 (inverted). H1 carriers face elevated tau-related disease risk — but H1 is not a single entity. It encompasses a family of sub-haplotypes, each defined by a unique combination of alleles at six tagging positions. rs3785883 defines the H1h sub-haplotype, a configuration that carries a distinctive risk profile separate from the well-characterised H1c sub-haplotype tracked by rs242557 and rs2471738.

The Mechanism

The rs3785883 A allele co-occurs with rs242557 G and rs2471738 C to form the H1h sub-haplotype (full composition: rs1467967=A, rs242557=G, rs3785883=A, rs2471738=C). This is structurally distinct from H1c (rs242557=A, rs2471738=T, rs3785883=G): the two sub-haplotypes carry the A allele at rs3785883 and rs242557 in opposite orientations. The linkage disequilibrium between rs3785883 and rs242557 is extremely low¹¹ extremely low
r² ≈ 0.01 measured in both healthy controls and PSP patients, confirming these SNPs are statistically and biologically independent.

The molecular consequence of the H1h configuration is not fully characterised, but the sub-haplotype pattern implicates altered tau isoform ratios or expression levels in neurons within specific motor circuits. The non-tremor dominant (NTD) phenotype of Parkinson's disease — characterised by postural instability and gait difficulty rather than resting tremor — is the clinical domain where H1h risk concentrates, suggesting a preferential effect on basal ganglia circuitry.

The Evidence

A 2016 study examining MAPT subhaplotype architecture across PD subtypes²² MAPT subhaplotype architecture across PD subtypes
Ezquerra et al. Genetic Architecture of MAPT Gene Region in Parkinson Disease Subtypes. Front Cell Neurosci, 2016 found that the H1h sub-haplotype was overrepresented in NTD-PD patients compared with controls with an OR of 2.9 (95% CI 1.3–6.3) that survived Bonferroni correction (p = 0.007). The overall PD association (uncorrected OR 2.6, p = 0.013) did not reach significance after correction. At the individual-SNP level, rs3785883 showed a nominally significant association with NTD-PD (OR 1.5, p = 0.044) that did not survive multiple-testing correction — the haplotype-level signal is stronger than the single-SNP signal, consistent with the variant acting as part of a combinatorial genetic background rather than as an independent causal allele.

Earlier subhaplotype work (Goris et al., 2007)³³ (Goris et al., 2007) established the key contrast: rs242557 (H1c) does not alter PD risk, while rs3785883 participates in a sub-haplotype block that does — precisely the opposite of the PSP/CBD pattern, where H1c dominates. This disease-specific partitioning of H1 sub-haplotype risk is a central insight of MAPT genetic architecture.

A Croatian cohort study of Alzheimer's disease biomarkers found both AA and GG genotypes at rs3785883 associated with pathological CSF and plasma biomarkers, though the authors noted the interpretation is ambiguous and flagged it for further investigation. A meta-analysis of MAPT variants in neurodegenerative diseases found only a nominally protective A-allele signal in Caucasians (OR 0.87) that disappeared after sensitivity analysis, providing no reliable AD risk signal for this SNP.

The overall evidence level is moderate: the H1h-NTD-PD association is supported by a single well-designed study with correction for multiple testing, but has not yet been replicated in independent cohorts. The AD biomarker data are preliminary and contradictory.

Practical Actions

Carriers of the A allele — particularly those homozygous AA — exist within the H1h sub-haplotype background and face modestly elevated risk for the akinetic-rigid/postural- instability variant of Parkinson's disease. The actionable implications are similar to other MAPT risk variants: prioritising cardiovascular and metabolic health (which modifies the timing and severity of tau-related neurodegeneration), regular monitoring for early motor symptoms, and physical activity targeting balance and postural stability. Aerobic exercise has been shown to promote tau clearance via glymphatic pathways and reduce neuroinflammation, making it particularly relevant here.

Interactions

rs3785883 (H1h) and rs242557 (H1c) are nearly independent (r² ≈ 0.01) and tag distinct disease risks: H1h → NTD-PD, H1c → PSP/CBD. An individual who carries the A allele at rs3785883 is unlikely to also carry the A allele at rs242557 on the same chromosomal background. Compound analysis of all six MAPT tagging positions (rs1467967, rs242557, rs3785883, rs2471738, del-In9, rs7521) provides the most complete sub-haplotype picture. rs17651213 (exon 3 splice regulator) adds a mechanistic layer: its G allele elevates 4-repeat tau isoforms across most H1 sub-haplotypes including H1h, potentially amplifying the H1h motor risk signal.

SLCO1B1 encodes the organic anion transporting polypeptide 1B1 (OATP1B1), a liver uptake transporter that moves statins from the blood into liver cells where they exert their cholesterol-lowering effect. When this transporter does not work properly, statins accumulate in the blood and muscle tissue instead of entering the liver, dramatically increasing the risk of myopathy¹¹ Myopathy: disease of muscle tissue, ranging from mild pain to serious breakdown.

The Mechanism

The SLCO1B1*5 variant²² rs4149056 causes a valine-to-alanine substitution at position 174³³ Amino acid change: valine to alanine at position 174 (V174A) in a transmembrane domain of the transporter. This reduces the transporter's ability to move statins into liver cells. The C allele produces a transporter with markedly reduced function, leading to higher systemic statin exposure -- approximately 40% higher simvastatin acid levels⁴⁴ 40% higher simvastatin acid levels
CPIC guideline for SLCO1B1 in heterozygous carriers.

The SEARCH Trial

The landmark SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) trial⁵⁵ SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) trial
SEARCH Collaborative Group. NEJM, 2008 identified SLCO1B1*5 as the primary genetic determinant of statin-induced myopathy. Homozygous carriers (CC) had a 17-fold increased risk of myopathy on simvastatin 80mg (OR 16.9, 95% CI 4.7-61.1), while heterozygous carriers (CT) had a 4.5-fold increased risk (OR 4.5, 95% CI 2.6-7.7). This finding led to the FDA limiting the maximum recommended dose of simvastatin to 40mg.

Not All Statins Are Equal

The risk varies significantly by statin type. Simvastatin is the highest risk because it relies heavily on SLCO1B1 for liver uptake. Pravastatin is the safest alternative because it enters liver cells through multiple pathways and is less dependent on SLCO1B1. Rosuvastatin has intermediate risk. Atorvastatin uses SLCO1B1 but has a wider therapeutic window than simvastatin. The 2022 CPIC guideline update⁶⁶ 2022 CPIC guideline update
Cooper-DeHoff RM et al. CPIC guideline for statins and SLCO1B1, ABCG2, CYP2C9. Clin Pharmacol Ther, 2022 now covers all statins, not just simvastatin.

Practical Implications

If you carry the C allele and ever need statin therapy, this information can prevent a potentially serious adverse reaction. Statin-induced myopathy ranges from mild muscle aches to rhabdomyolysis⁷⁷ Rhabdomyolysis: severe muscle breakdown that releases proteins into the blood, potentially damaging the kidneys. Choosing the right statin and dose based on your SLCO1B1 genotype is one of the clearest wins in clinical pharmacogenomics.

COMT (catechol-O-methyltransferase) ¹¹ COMT methylates and inactivates catechol-containing compounds including dopamine, estrogens, and certain drugs is an enzyme that breaks down catecholamines — dopamine, norepinephrine, and epinephrine — by adding a methyl group from SAM. The Val158Met variant (rs4680) is one of the most fascinating genetic variants because it doesn't have a clear "good" or "bad" allele. Instead, each version confers different cognitive and behavioral trade-offs.

The Mechanism

The A allele (Met) ²² Val158Met: valine-to-methionine substitution at position 158 of the enzyme (p.Val158Met) produces an enzyme that works 3-4 times slower than the G allele (Val) version. Methionine at position 158 makes the enzyme thermolabile, reducing its catalytic efficiency at body temperature. Slower COMT means dopamine and other catecholamines persist longer in the prefrontal cortex, the brain region responsible for working memory, planning, and executive function ³³ The prefrontal cortex is uniquely dependent on COMT for dopamine clearance because it lacks the dopamine transporter found in other brain regions.

Warrior vs. Worrier

The GG (Val/Val) "warrior" genotype breaks down dopamine quickly, resulting in lower prefrontal dopamine levels. Warriors perform better under stress and pressure but may have less optimal baseline cognitive performance. The AA (Met/Met) "worrier" genotype maintains higher dopamine levels, leading to better cognitive performance in calm conditions but greater vulnerability to stress and anxiety. This cognitive trade-off was demonstrated in a landmark study by Egan et al.⁴⁴ landmark study by Egan et al.
Egan MF et al. COMT Val158Met effects on prefrontal cortex function, 2001.

Pain and Opioid Response

COMT genotype significantly affects pain sensitivity and opioid response. The Zubieta landmark study⁵⁵ Zubieta landmark study
Zubieta JK et al. COMT Val158Met affects mu-opioid neurotransmitter responses to pain, 2003 showed that Met/Met individuals have diminished mu-opioid responses to pain. A study on cancer patients⁶⁶ study on cancer patients
Rakvag TT et al. COMT Val158Met influences morphine requirements in cancer pain patients, 2005 found that Val/Val patients needed 63% higher morphine doses than Met/Met patients. A meta-analysis⁷⁷ meta-analysis
Chen YC et al. COMT Val158Met and postoperative opioid consumption, 2018 confirmed reduced opioid consumption in Met carriers.

The Methylation Connection

COMT uses SAM as its methyl donor, directly linking it to the methylation cycle. Slow COMT (AA) individuals are more sensitive to methyl donors like methylfolate, methylB12, and TMG ⁸⁸ Trimethylglycine (betaine): a potent methyl donor derived from choline that feeds into the methylation cycle (trimethylglycine). Excess methyl groups can overstimulate an already slow COMT pathway, causing anxiety, irritability, and insomnia. This is why some people feel worse on high-dose methylated B vitamins.

Practical Implications

If you are AA (slow COMT), be cautious with methyl donor supplements. Start with low doses and increase gradually. Folinic acid and hydroxocobalamin are gentler alternatives to methylfolate and methylcobalamin. Glycine (2-4g) can help buffer excess methyl groups. If you are GG (fast COMT), you generally tolerate methyl donors well and may even benefit from them. This variant is key to personalizing your methylation support strategy.

Interactions

COMT interacts with MTHFR (rs1801133) — MTHFR determines methylfolate production while COMT determines tolerance. Someone with both MTHFR AA (low methylfolate) and COMT AA (slow methylation) faces a complex supplementation challenge.

DYRK1B (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1B) is a serine/threonine kinase that plays a pivotal role in adipogenesis, glucose homeostasis, and hedgehog/Wnt signaling pathways. When functioning normally, DYRK1B helps restrain fat cell differentiation and maintain metabolic balance. The H90P variant disrupts a critical structural element of the kinase, triggering a cascade of metabolic consequences that manifest as AOMS3¹¹ AOMS3
Abdominal Obesity-Metabolic Syndrome 3, OMIM #615812, a rare autosomal dominant condition causing severe early-onset metabolic syndrome.

The Mechanism

The H90P mutation replaces histidine with proline at position 90 of the protein, within the DYRK homology (DH) box²² DYRK homology (DH) box
A conserved structural element immediately preceding the catalytic domain, critical for proper kinase folding through tyrosine autophosphorylation. This box normally stabilizes interactions with the catalytic domain during protein maturation. The substitution impairs tyrosine autophosphorylation (reduced ~80% versus wild-type), causing mutant DYRK1B to misfold and accumulate in detergent-insoluble cytoplasmic aggregates. The result is a net loss of functional DYRK1B activity.

Without adequate DYRK1B function, two main pathological effects follow: enhanced adipogenesis — preadipocytes differentiate more readily into fat cells, leading to accelerated visceral fat accumulation — and impaired glucose regulation — hepatic glucose-6-phosphatase expression rises, driving excess hepatic glucose output and contributing to frank type 2 diabetes. Downstream, the RAS–RAF–MEK pathway is dysregulated, and suppression of hedgehog and Wnt signaling further promotes adipogenic commitment of precursor cells.

The Evidence

The H90P variant was first described in 2014³³ first described in 2014
Keramati AR et al. A form of the metabolic syndrome associated with mutations in DYRK1B. N Engl J Med. 2014;370(20):1909-19 through genetic linkage analysis and whole-exome sequencing of three large Iranian families with autosomal dominant metabolic syndrome. H90P co-segregated with disease in an ethnically distinct family alongside the R102C mutation, producing an identical phenotype: early-onset central obesity, type 2 diabetes, hypertension, and coronary artery disease (myocardial infarction between ages 50–60). No unaffected carrier was identified in any family, suggesting high penetrance.

Molecular characterization⁴⁴ Molecular characterization
Abu Jhaisha S et al. DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain. Sci Rep. 2017;7(1):7602 confirmed that H90P — unlike the structurally intact mature kinase — fails to properly autophosphorylate on tyrosine. The mutant protein relies abnormally on the HSP90–CDC37 chaperone complex for stability, rendering it sensitive to HSP90 inhibition. This chaperone dependency is a therapeutic vulnerability that has been proposed as a drug target.

A 2024 Diabetes Care study⁵⁵ 2024 Diabetes Care study
Folon L et al. Pathogenic, Total Loss-of-Function DYRK1B Variants Cause Monogenic Obesity Associated With Type 2 Diabetes. Diabetes Care. 2024 across 9,353 participants quantified the effect: pathogenic DYRK1B loss-of-function variants were associated with an 8.0-unit higher BMI (OR 7.9 for obesity) and OR 4.8 for type 2 diabetes. The same study confirmed that H90P-class variants cause monogenic obesity, a clinically distinct entity from polygenic common obesity.

What This Means Clinically

AOMS3 is frequently misdiagnosed. A 2024 case report⁶⁶ 2024 case report
Abdominal Obesity-Metabolic Syndrome 3 Misclassified as Type 1 Diabetes Mellitus. 2024 documented a patient treated with 225 units of insulin daily for 15 years before the DYRK1B mutation was identified. Switching to oral agents (metformin, pioglitazone, dapagliflozin) plus semaglutide reduced HbA1c from 13% to 7% within 6 months — a result insulin alone had never achieved. DYRK1B carriers respond better to insulin-sensitizing agents and GLP-1 receptor agonists than to exogenous insulin.

Because this is an autosomal dominant condition, each first-degree relative of a carrier has a 50% chance of inheriting the variant. Early identification before metabolic complications emerge allows preventive intervention.

H90R — The Second Allele at This Codon

This locus is multi-allelic: in addition to H90P (T>G), a T>C change at the same position produces H90R (His90Arg). H90R has not been individually characterised in cell-based assays, but its structural logic is equivalent — arginine, like proline, disrupts the local backbone geometry of the DH box required for tyrosine autophosphorylation during kinase maturation. Population data (gnomAD v4 exomes, ~3 alleles in 800,000) confirms the same extreme rarity as H90P. H90R is classified as likely pathogenic by structural inference; clinical management for carriers is identical to H90P.

Interactions

H90P and H90R act at the same codon as the R102C variant (encoded by a distinct mutation in the same DYRK1B gene at codon 102). All three disrupt the DH box and produce clinically indistinguishable AOMS3. Functional studies on H90P and R102C show overlapping mechanisms — impaired DH-box-mediated kinase maturation, enhanced chaperone dependency, and downstream adipogenic dysregulation — making them phenotypic equivalents despite different amino acid substitutions.

Your thyroid gland operates like a thermostat: the pituitary hormone TSH (thyroid-stimulating hormone)¹¹ TSH (thyroid-stimulating hormone)
Thyrotropin — secreted by the anterior pituitary, it binds TSH receptors on thyroid follicular cells and drives synthesis and release of T3 and T4. The pituitary adjusts TSH output based on feedback from circulating thyroid hormone levels signals the thyroid to produce more or less hormone. But the gain on that thermostat varies between individuals — and PDE8B is a key control knob.

PDE8B encodes phosphodiesterase 8B²² phosphodiesterase 8B
A cyclic nucleotide phosphodiesterase highly expressed in thyroid tissue that specifically degrades cAMP (cyclic adenosine monophosphate). cAMP is the second messenger through which TSH stimulates thyroid hormone production an enzyme that degrades cAMP inside thyroid follicular cells. When TSH binds its receptor, it triggers a cAMP surge that drives thyroid hormone synthesis. PDE8B acts as a brake on that surge: higher PDE8B activity → faster cAMP degradation → weaker thyroid response to TSH → the pituitary compensates by raising circulating TSH levels. rs6885099 sits in intron 1 of PDE8B and influences how much of this enzyme the thyroid makes.

The Mechanism

rs6885099 is an intronic quantitative trait locus (QTL)³³ quantitative trait locus (QTL)
A genetic variant that influences the quantity of a measurable trait — here, serum TSH levels — without altering protein structure. These variants typically act through regulatory elements (enhancers, splicing signals) embedded within introns or non-coding regions affecting PDE8B gene expression in thyroid tissue. The G allele is associated with higher PDE8B activity or expression, which accelerates cAMP degradation and raises the thyroid's effective TSH threshold. The result is a genetically-programmed upward shift in the individual's TSH set-point — circulating TSH is chronically higher relative to tissue thyroid hormone levels.

Critically, this is not the same as thyroid disease: individuals with GG or AG genotypes have a higher TSH set-point but are often euthyroid (normal circulating T3/T4). However, they may tip into subclinical hypothyroidism⁴⁴ subclinical hypothyroidism
TSH above the upper reference range with normal free T4 — the most common form of thyroid dysfunction, affecting 4-10% of the general population and up to 20% of women over 60 at lower absolute levels of thyroid dysfunction, and when they do require levothyroxine replacement, their genetically higher set-point may require a higher dose to suppress TSH adequately.

The Evidence

The largest study to date is the Rand et al. 2025⁵⁵ Rand et al. 2025
Rand SA et al. Genome-wide association study and polygenic risk prediction of hypothyroidism. Nat Genet, 2025 meta-analysis in 113,393 hypothyroidism cases and 1,065,268 controls — identifying 350 associated loci. rs6885099-G showed one of the strongest signals (beta = 0.10, p = 1×10⁻⁹³), confirming PDE8B as a major determinant of hypothyroidism susceptibility.

The TSH-lowering effect of the A allele was established by Porcu et al. 2013⁶⁶ Porcu et al. 2013
Porcu E et al. A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function. PLoS Genet, 2013 in up to 26,420 euthyroid subjects: the rs6885099-A allele reduced log-TSH by 0.141 units (p = 2×10⁻²⁶), with a stronger effect in males (beta −0.168, p = 3×10⁻³⁸) than females (beta −0.12, p = 6×10⁻²⁴), suggesting partial sex-hormone modulation of PDE8B activity.

Soto-Pedre et al. 2017⁷⁷ Soto-Pedre et al. 2017
Soto-Pedre E et al. Replication confirms the association of loci in FOXE1, PDE8B, CAPZB and PDE10A with thyroid traits: a GoDARTS study. Pharmacogenet Genomics, 2017 confirmed the locus in 1,703 hypothyroidism cases and 9,457 controls; PDE8B variants collectively explained 6.8% of TSH variance.

Wade et al. 2025⁸⁸ Wade et al. 2025
Wade AN et al. Strength of Genetic Associations with Thyrotropin Values Differs Between Populations with Similarity to African and European Reference Populations. Thyroid, 2025 found that PDE8B was not significantly associated with TSH in African-ancestry populations despite strong effects in Europeans — an important caveat for interpreting the result in non-European individuals.

Practical Actions

For GG and AG individuals, the main clinical implications are: (1) awareness of a higher baseline TSH that may require lower thresholds for hypothyroidism diagnosis, (2) for those already on levothyroxine, the TSH target may need adjustment relative to standard ranges, and (3) monitoring iodine intake — since thyroid hormone synthesis requires iodine, marginal iodine status combined with a high-PDE8B set-point amplifies hypothyroidism risk.

Selenium supports deiodinase enzymes⁹⁹ deiodinase enzymes
Selenoproteins that convert the storage form T4 to the active T3; selenium deficiency impairs this conversion and may worsen functional hypothyroidism even when TSH is only mildly elevated that convert inactive T4 to active T3. GG carriers benefit specifically from ensuring selenium adequacy.

Interactions

rs4704397 (PDE8B intron 1) is in strong linkage disequilibrium with rs6885099 and captures overlapping variance. Both variants have been studied for TSH effects; their combined information adds little beyond either alone.

rs2046045 (PDE8B intron 1) is a third correlated variant in the same LD block, consistently identified in GWAS of TSH and hypothyroidism.

rs11206244 (TPO — thyroid peroxidase) affects thyroid hormone synthesis directly rather than cAMP signaling, acting through a different pathway. Individuals combining a high PDE8B set-point (this SNP) with impaired TPO activity may have compounded hypothyroidism risk.

Endothelial lipase (EL), encoded by the LIPG gene on chromosome 18, is the primary enzyme responsible for breaking down the phospholipid surface of HDL particles¹¹ HDL particles
High-density lipoprotein — the "good cholesterol" carrier that transports cholesterol from peripheral tissues back to the liver for clearance. Unlike lipoprotein lipase (which targets triglyceride-rich VLDL and chylomicrons), EL preferentially hydrolyzes HDL phospholipids. Higher EL activity accelerates HDL catabolism, reducing circulating HDL-C. The rs9951026 variant is an intronic tag SNP in LIPG that marks a broader haplotype structure associated with modestly altered LDL cholesterol and apolipoprotein B levels — with an important twist: the effect on lipid profiles is substantially modified by physical activity.

The Mechanism

As a non-coding intronic variant, rs9951026 does not directly change any amino acid in the endothelial lipase protein. Its association with lipid traits derives from linkage disequilibrium²² linkage disequilibrium
LD — the tendency for nearby genetic variants to be inherited together on the same chromosomal segment, so that one variant predicts the presence of another with functional regulatory variants in the same LIPG haplotype block. The TTACA LIPG haplotype — spanning rs2000812, rs2000813, rs8093249, rs2276269, and rs9951026 — has been associated with higher LDL cholesterol and apolipoprotein B concentrations in population studies, suggesting the haplotype affects either LIPG expression levels or broader lipoprotein remodeling through regulatory elements in the same LD block.

LIPG expression is upregulated by pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-6³³ pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-6
The inflammatory connection explains why conditions like atherosclerosis, infection, and metabolic syndrome all tend to lower HDL-C — inflammation drives LIPG activity, which then degrades HDL faster. Physical activity suppresses this inflammatory signaling, which may explain why the lipid associations at rs9951026 are primarily visible in sedentary individuals: active individuals have lower baseline LIPG expression through reduced inflammation, partially neutralizing the haplotype effect.

The Evidence

Salazar-Tortosa et al. (2022)⁴⁴ Salazar-Tortosa et al. (2022)
Interplay of physical activity and genetic variants of the endothelial lipase on cardiovascular disease risk factors; 1,057 European adolescents from the HELENA Study aged 12–18 years; Pediatric Research found that the minor G allele of rs9951026 was associated with lower CVD risk factors related to the lipid profile. Critically, the beneficial allele associations were observed specifically in physically active adolescents — not in sedentary participants. The gene-physical activity interaction was statistically significant for rs9951026 (along with rs2000813 and rs2276269), indicating that the genetic effect on cardiovascular risk factors depends substantially on activity level.

The broader LIPG haplotype context comes from Hutter et al. (2006)⁵⁵ Hutter et al. (2006)
Association of endothelial lipase gene haplotypes with HDL cholesterol subfractions and apolipoprotein AI plasma levels in Japanese Americans; 541 adult participants; Atherosclerosis, which found that LIPG haplotypes — including variants at the same chromosomal region as rs9951026 — influenced HDL3 cholesterol (p=0.005) and apolipoprotein A-I levels (p=0.002), with favorable haplotype combinations showing lower apolipoprotein B and LDL cholesterol (p=0.001 and p=0.015 respectively).

Edmondson et al. (2009)⁶⁶ Edmondson et al. (2009)
Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans; 585 participants with extreme HDL phenotypes plus meta-analysis of ~3,845 participants; J Clin Invest established the fundamental LIPG-HDL relationship: rare loss-of-function mutations in LIPG raise HDL by approximately 8–11 mg/dL (10–16%), validating EL as a key determinant of circulating HDL levels in humans. While rs9951026 is not a loss-of-function variant, it sits in a haplotype context that modulates EL's functional output.

Practical Actions

The most important insight from the evidence is the gene-activity interaction: the A allele haplotype's association with less favorable lipid levels is attenuated or reversed in physically active individuals. This is not a reason to reduce cardiorespiratory training — it is a signal that your genetic lipid risk from this variant is disproportionately responsive to activity levels compared to the population average. Cardiovascular exercise reduces systemic inflammation, which in turn suppresses LIPG expression and slows HDL catabolism, partially compensating for an unfavorable LIPG haplotype.

For AA homozygotes, the standard lipid panel remains the key monitoring tool. Saturated fat quality, omega-3 intake, and aerobic activity are the primary levers — and for this genotype, activity matters more than average. Regular fasting lipid panels (including LDL-C and apolipoprotein B if available) provide the most actionable feedback.

Interactions

rs9951026 is part of a multi-SNP LIPG haplotype that includes rs2000813 (the Thr111Ile coding variant), rs3813082, and rs2276269. Haplotype analyses consistently show stronger lipid associations than any single SNP from this block. The rs2000813 T allele tags a 5'UTR regulatory variant (rs34474737) that reduces LIPG promoter activity; individuals carrying the full TTACA haplotype carry both the rs9951026 A allele and the rs2000813 T allele, with the combined haplotype showing stronger LDL and apoB associations than either SNP alone.

The gene-physical inactivity interaction found for nearby rs6507931 (LIPG i24582) in the GOLDN study — where screen time above 2.6 h/day reduced HDL-C and HDL particle size specifically in TT carriers — suggests a general pattern of LIPG-activity interaction across the gene's haplotype structure. Users with both rs9951026 AA (high-risk LIPG haplotype) and rs2000813 CC (standard EL expression, no HDL-raising regulatory haplotype benefit) represent a combined LIPG context where aerobic activity is particularly valuable for maintaining HDL quality.